FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,												
1. Name and Address of Reporting Person* Graves Adrienne L					2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [OCUL]								Chec	k all applic	cable)	g Pers	son(s) to Issi		
(Last)			(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/24/2024								J	Director Officer (give title below)		10% Owr Other (sp below)		-
C/O OCULAR THERAPEUTIX, INC. 15 CROSBY DRIVE					4.1	If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person					
(Street) BEDFOR	RD M	[A	01730												Form fi Person		e than	One Repor	ting
(City)					R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	ole I - Nor	n-Deriv	vative														
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date					Execution Dat			3. Transa Code (I			ecurities Acquired (A) osed Of (D) (Instr. 3, 4				es ally Following	Form (D) o	r Indirect	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	Prio	е	Reported Transact (Instr. 3 a	tion(s)			Instr. 4)
Common Stock 07/24/				4/202	1/2024		A		12,000	0 ⁽¹⁾ A		<mark>0</mark>	36,000			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			. Price of Perivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration late	Title	Amou or Numb of Share	ər					
Stock Option (Right to Buy)	\$7.91	07/24/2024			A		36,000		(2)	0	7/23/2034	Common Stock	36,00	00	\$0	36,000)	D	

Explanation of Responses:

1. On July 24, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

/s/Donald Notman, Attorneyin-Fact for Adrienne L. Graves

07/26/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.